iBio's business strategy is to broadly participate in the markets that the iBio Technology platform addresses.
- Early-stage Biotech companies
- Large pharma
- Universities and University commercial spin-outs
- Government Agencies- DARPA, NIH
- International Clients
- Tech transfer and facilities development in emerging countries – Brasil, South Africa
- New biotherapeutic development – Japan, China